The short version of Synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
== Efficacy == As of 2021, many thousands of papers had been published on the efficacy of acupuncture for the treatment of various adult health conditions, but there was no robust evidence it was beneficial for anything, except shoulder pain and fibromyalgia. The evidence for its efficacy in shoulder pain is low quality and includes only two studies. Its efficacy for fibromyalgia does not appear to be clinically significant. For Science-Based Medicine, Steven Novella wrote that the overall pattern of evidence was reminiscent of that for homeopathy, compatible with the hypothesis that most, if not all, benefits were due to the placebo effect, and strongly suggestive that acupuncture had no beneficial therapeutic effects at all. Harriet Hall noticed that according to Edzard Ernst in 2011, systematic reviews agreed that acupuncture works for neck pain, but not for every other pain—and that makes its whole enterprise suspicious. A 2024 review concluded that it is no more effective than sham acupuncture for neck pain reduction.
== Abbreviations and nomenclature == Abbreviations for "arbitrary unit" include: arb. unit, arb. u., AU, and a.u. Among these, "AU" and "a.u." are common abbreviations for astronomical units and atomic units. For this reason, Physical Review journals, the Japanese Journal of Applied Physics, and an increasing number of other academic journals, recommend against using "a.u." (Jpn. J. Appl. Phys recommends "arb. unit" instead). In UCUM, arbitrary unit is represented as "[arb'U]". While arbitrary unit is not a formally recognized unit, IUPAC and IFCC recognize the need to deal with "unknown units", and decided in 2008 to use the term "procedure defined unit" in their database. The decision forbids using factors or denominators in conjunction with p.d.u. (such as "p.d.u./L").
== Golf scandals == Jane Blalock cheating controversy – one of the LPGA Tour's top players, Jane Blalock, was accused of illegally marking her golf ball on the green. She was suspended and fined by the tour, but Blalock in turn filed suit and won an injunction that allowed her to continue playing. Blalock eventually won her lawsuit and she and the LPGA reached an out-of-court settlement. Vijay Singh, a former number one golfer in the world, was suspended from the PGA Tour for using deer antler spray, which violated the PGA Tour Anti-Doping Policy. Likewise in 1985, Vijay Singh was caught erasing his score on a hole and replacing it with a lower score after the scorecard had been signed. Once the rules officials confirmed the allegations, Singh was banned from the Asian Tour. To this day, Singh has not acknowledged that he cheated.
Sources: en.wikipedia.org
As of 2018 there are clinical trials underway testing the efficacy and safety of these treatments. For over a century, bacteria have been used in agriculture. Crops have been inoculated with Rhizobia (and more recently Azospirillum) to increase their production or to allow them to be grown outside their original habitat. Application of Bacillus thuringiensis (Bt) and other bacteria can help protect crops from insect infestation and plant diseases. With advances in genetic engineering, these bacteria have been manipulated for increased efficiency and expanded host range. Markers have also been added to aid in tracing the spread of the bacteria. The bacteria that naturally colonize certain crops have also been modified, in some cases to express the Bt genes responsible for pest resistance. Pseudomonas strains of bacteria cause frost damage by nucleating water into ice crystals around themselves. This led to the development of ice-minus bacteria, which have the ice-forming genes removed. When applied to crops they can compete with the non-modified bacteria and confer some frost resistance.
Colloidal gold has been used by artists for centuries because of the nanoparticle's interactions with visible light. Gold nanoparticles absorb and scatter light resulting in colours ranging from vibrant reds (smaller particles) to blues to black and finally to clear and colorless (larger particles), depending on particle size, shape, local refractive index, and aggregation state. These colors occur because of a phenomenon called localized surface plasmon resonance (LSPR), in which conduction electrons on the surface of the nanoparticle oscillate in resonance with incident light.
Jamal al-Husayni Tewfiq al-Husayni Yusif Sahyun Kamil al-Dajani Emile al-Ghury Rafiq al-Tamimi and Anwar al-Khatib (all members of or affiliated with the Palestine Arab Party) Izzat Tannous (an independent Christian medical doctor) Antone Attallah (a member of the Greek Orthodox community) Ahmad al-Shukayri (a lawyer from Acre and an Arab nationalist) Sami Taha – head of Palestine Arab Workers Society Yousef Haikal (the mayor of Jaffa, who was politically independent) The Istiqlal Party and other nationalist groups objected to these moves, and formed a rival Arab Higher Front. In May 1946, the Arab League ordered the dissolution of the AHC and Arab Higher Front and formed a five-member Arab Higher Executive, under Amin al-Husayni's chairmanship, and based in Cairo. The new AHE consisted of:
== Interaction with other nutrients == Selenium interactes with iodine and vitamin E; see section "Deficiency" above. Selenium interacts with other minerals, such as zinc and copper. High doses of selenium supplements in pregnant animals might disturb the zinc:copper ratio and lead to zinc reduction; in such treatment cases, zinc levels should be monitored. Further studies are needed to confirm these interactions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.